DiaMedica Pharma (DMAC): Volume dana dhuwit perusahaan

The prospects for DiaMedica Therapeutics (DMAC) depend on the results of DM199 stroke trials and FDA approval. This cash liquidity chart visualizes the current cash reserves, where 0.04 reflects the latest metric value. Meanwhile, DiaMedica Therapeutics is implementing recombinant proteins to restore organ blood flow, remaining independent of macroeconomic trends and focusing on the protection of brain neurons.
Rincian metrik lan analitis perusahaan DiaMedica Therapeutics Inc. (DMAC)

The amount of cash reflects the issuer's immediate liquidity and serves as a key indicator of financial viability. This metric aggregates account balances, allowing for the tracking of the burn rate without quarterly distortions. By analyzing cash on hand, an investor assesses the margin of safety for operational activities. For DiaMedica Therapeutics (DMAC), this resource is critically important for funding clinical trials of unique blood flow restoration drugs.